Journal article · 2026 · Open access

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study

Miao Cai, Taeyoung Choi, Yan Xie, Ziyad Al‐Aly

BMJ, 392, e086886 · Published 4 March 2026 · DOI 10.1136/bmj-2025-086886

Open PDFView at the publisherCite this paper

In brief

“Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study” is a 2026 journal article by Miao Cai and 3 co-authors, published in BMJ. OpenAlex counts 62 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC licence: the full text is free to read at BMJ.

Citations
62
Most cited in
2026 (62)
Field-weighted impact
198.83
References
70
Authors
4

Abstract

OBJECTIVES: To investigate whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders (SUDs) in people with no history of SUDs (protocol 1) and with reduced risk of SUD related adverse clinical outcomes among people with a pre-existing SUD (protocol 2). DESIGN: Emulation of eight parallel, new user, active comparator target trials using electronic health records: seven trials for each incident SUD outcome (protocol 1) and one trial for adverse outcomes in people with pre-existing SUD (protocol 2). SETTING: US Department of Veterans Affairs. PARTICIPANTS: From a base population of 606 434 US veterans with type 2 diabetes, participants were assigned to one of the two protocols and followed for up to three years. Trial 1 (primary trial) of protocol 1 included 524 817 initiators of GLP-1 receptor agonists (n=124 001) or sodium-glucose cotransporter-2 (SGLT-2) inhibitors (n=400 816). Protocol 2 included 81 617 initiators of GLP-1 receptor agonists (n=16 768) and SGLT-2 inhibitors (n=64 849). MAIN OUTCOME MEASURES: Incident outcomes were alcohol, cannabis, cocaine, nicotine, opioid, other SUDs, and a composite of these outcomes. Adverse outcomes among participants with pre-existing SUDs included SUD related emergency department visits, SUD related hospital admissions, and SUD related mortality, and drug overdose and suicidal ideation or attempt. Hazard ratios and net three year risk difference (NRD) per 1000 people were reported based on inverse probability weighted (standardised mortality ratio weighted) cause specific Cox survival models. RESULTS: Compared with initiation of SGLT-2 inhibitors, initiation of GLP-1 receptor agonists was associated with reduced risk of disorders related to alcohol use (hazard ratio 0.82 (95% confidence interval (CI) 0.78 to 0.85); NRD per 1000 people -5.57 (-6.61 to -4.53)), cannabis use (0.86 (0.81 to 0.90), NRD -2.25 (-3.00 to -1.50)), cocaine use (0.80 (0.72 to 0.88), NRD -0.97 (-1.37 to -0.57)), nicotine use (0.80 (0.74 to 0.87), NRD -1.64 (-2.19 to -1.09)), and opioid use (0.75 (0.67 to 0.85), NRD -0.86 (-1.19 to -0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD -1.12 (-1.68 to -0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD -6.61 (-7.95 to -5.26)). Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD -8.92 (-11.59 to -6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD -6.23 (-8.73 to -3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD -1.52 (-2.32 to -0.72)), and drug overdose…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cai, M., Choi, T., Xie, Y., & Al‐Aly, Z. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ, 392, e086886. https://doi.org/10.1136/bmj-2025-086886

MLA 9

Cai, Miao, et al. “Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.” BMJ, vol. 392, 2026, p. e086886. https://doi.org/10.1136/bmj-2025-086886.

Chicago

Cai, Miao, Taeyoung Choi, Yan Xie, and Ziyad Al‐Aly. 2026. “Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.” BMJ 392: e086886. https://doi.org/10.1136/bmj-2025-086886.

Harvard

Cai, M. et al. (2026) ‘Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study’, BMJ, 392, p. e086886. doi:10.1136/bmj-2025-086886.

IEEE

M. Cai, T. Choi, Y. Xie, and Z. Al‐Aly, “Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study,” BMJ, vol. 392, p. e086886, 2026, doi: 10.1136/bmj-2025-086886.

BibTeX

@article{cai2026glucagon,
  title     = {{Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study}},
  author    = {Cai, Miao and Choi, Taeyoung and Xie, Yan and Al‐Aly, Ziyad},
  journal   = {BMJ},
  year      = {2026},
  volume    = {392},
  pages     = {e086886},
  doi       = {10.1136/bmj-2025-086886},
  url       = {https://doi.org/10.1136/bmj-2025-086886}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management

  • GLP-1 receptor agonists
  • substance use disorders
  • type 2 diabetes
  • veterans
  • SGLT2 inhibitors
  • alcoholism
  • cannabis use disorder
  • opioid use disorder

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Cai, M., Choi, T., Xie, Y., & Al‐Aly, Z. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ, 392, e086886. https://doi.org/10.1136/bmj-2025-086886

How many times has this paper been cited?

62 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at BMJ: sign in and open the PDF from this page.

Who wrote this paper?

Miao Cai, Taeyoung Choi, Yan Xie, Ziyad Al‐Aly.

What is the DOI of this paper?

10.1136/bmj-2025-086886, permanently at https://doi.org/10.1136/bmj-2025-086886. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.